Fast Disintegrating Combination Tablet of Taste Masked Levocetrizine Dihydrochloride and Montelukast Sodium: Formulation Design, Development, and Characterization

Table 19

Dissolution profile of stability study batch K5.

% Cumulative drug release in phosphate buffer (pH 6.8)—Kyron-T-104 (SSG + CCS)
Month batch →	0		1		2		3
Time (min) ↓	L	M	L	M	L	M	L	M
5	23.72	22.61	24.23	21.32	27.73	25.64	26.23	21.13
10	34.28	34.56	31.69	35.58	39.49	40.11	43.42	35.20
15	48.15	52.23	49.01	54.73	50.72	53.87	59.68	49.32
20	65.29	64.79	61.72	63.29	67.87	68.91	81.91	65.44
25	80.38	84.73	80.44	79.48	82.13	81.17	93.86	79.54
30	95.89	92.19	94.11	91.08	94.37	90.54	91.78	88.62

L: Levocetrizine dihydrochloride; M: Montelukast sodium.